Assays |
Analyte |
Class |
Matrix |
Extraction Method |
Internal Standard |
Range (ng/mL) |
Antiretrovirals - Plasma |
Amprenavir |
PI |
Plasma |
Protein precipitation |
Quinoxaline |
10 - 10,000 |
Atazanavir |
PI |
Plasma |
Protein precipitation |
Atazanvir-d5 |
10 - 10,000 |
Bictegravir |
INSTI |
Plasma |
Protein precipitation |
Dolutegravir-d5 |
10 - 10,000 |
Cenicriviroc |
CCR5 inhibitor |
Plasma |
Protein precipitation |
Cenicriviroc-d7 |
5-1000 |
Cobicistat |
PK enhancer |
Plasma |
Liquid-liquid |
Quinoxaline |
10-4000 |
Darunavir |
PI |
Plasma |
Protein precipitation |
Darunavir-d9 |
15 - 15,000 |
Dolutegravir |
INSTI |
Plasma |
Liquid-Liquid |
Dolutegravir-d5 |
10-4000 |
Efavirenz |
NNRTI |
Plasma |
Protein precipitation |
13C6-Efavirenz |
25 - 10,000 |
7-Hydroxy Efavirenz |
NNRTI |
Plasma |
Protein precipitation |
Hexobarbital |
5 - 5,000 |
8-Hydroxy Efavirenz |
NNRTI |
Plasma |
Protein precipitation |
Hexobarbital |
5 - 5,000 |
Elvitegravir |
INSTI |
Plasma |
Liquid-liquid |
Elvitegravir-d6 |
10-4000 |
Emtricitabine |
NRTI |
Plasma |
Protein precipitation |
2-chloroadenosine |
5 - 5,000 |
Etraivrine |
NNRTI |
Plasma |
Protein precipitation |
Etravirine-d8 |
5 - 5,000 |
Lamivudine |
NRTI |
Plasma |
Protein precipitation |
2-chloroadenosine |
5 - 5,000 |
Lopinavir |
PI |
Plasma |
Protein precipitation |
Lopinavir-d8 |
15 - 15,000 |
Maraviroc |
CCR5 inhibitor |
Plasma |
Protein precipitation |
Maraviroc-d6 |
2.5 - 2,500 |
Nevirapine |
NNRTI |
Plasma |
Protein precipitation |
Nevirapine-d5 |
10 - 10,000 |
Raltegravir |
INSTI |
Plasma |
Protein precipitation |
Quinoxaline |
5 - 5,000 |
Rilpivirine |
NNRTI |
Plasma |
Protein precipitation |
13C-d4-rilpivirine |
0.5 - 2000 |
Ritonavir |
PI |
Plasma |
Protein precipitation |
Ritonavir-d6 |
5 - 5,000 |
Saquinaivr |
PI |
Plasma |
Protein precipitation |
Quinoxaline |
10 - 10,000 |
Tenofovir |
NRTI |
Plasma |
Protein precipitation |
2-chloroadenosine |
5 - 5,000 |
Antiretrovirals – CSF |
Amprenavir |
PI |
CSF |
Protein precipitation |
Quinoxaline |
1.95 - 250 |
Atazanavir |
PI |
CSF |
Protein precipitation |
Atazanavir-d5 |
1.95 - 250 |
Bictegravir |
INSTI |
CSF |
Protein precipitation |
Dolutegravir-d5 |
1.0 - 100 |
Cenicriviroc |
CCR5 inhibitor |
CSF |
Protein precipitation |
Cenicriviroc-d7 |
0.241-15 |
Darunavir |
PI |
CSF |
Protein precipitation |
Darunavir-d9 |
1.95 - 250 |
Efavirenz |
NNRTI |
CSF |
Liquid-liquid |
13C6-Efavirenz |
0.5 - 2,500 |
7-Hydroxy Efavirenz |
NNRTI |
CSF |
Liquid-liquid |
13C6-Efavirenz |
0.01 - 50 |
8-Hydroxy Efavirenz |
NNRTI |
CSF |
Liquid-liquid |
13C6-Efavirenz |
0.05 - 250 |
Etravirine |
NNRTI |
CSF |
Protein precipitation |
Etravirine-d8 |
1.95 - 250 |
Lopinavir |
PI |
CSF |
Protein precipitation |
Lopinavir-d8 |
0.78 - 100 |
Maraviroc |
CCR5 inhibitor |
CSF |
Protein precipitation |
Maraviroc-d6 |
0.78 - 100 |
Nevirapine |
NNRTI |
CSF |
Protein precipitation |
Nevirapine-d5 |
19.53 - 2,500 |
Raltegravir |
INSTI |
CSF |
Protein precipitation |
Raltegravir-d6 |
1.95 - 250 |
Rilpivirine |
NNRTI |
CSF |
Protein precipitation |
13C-d4-rilpivirine |
1.95 - 250 |
Ritonavir |
PI |
CSF |
Protein precipitation |
Ritonavir-d6 |
0.78 - 100 |
Antiretrovirals – PBMCs |
Darunavir |
PI |
PBMC |
Direct injection |
Quinoxaline |
0 - 150 |
Emtricitabine- Triphosphate |
NRTI |
PBMC |
Direct injection |
2-chloroadenosine 5’-triphosphate |
0.5 - 100 |
Lamivudine- Triphosphate |
NRTI |
PBMC |
Direct injection |
2-chloroadenosine 5’-triphosphate |
0.75 - 100 |
Lopinavir |
PI |
PBMC |
Direct injection |
Quinoxaline |
0 - 150 |
Raltegravir |
INSTI |
PBMC |
Direct injection |
Quinoxaline |
0 - 150 |
Ritonavir |
PI |
PBMC |
Direct injection |
Quinoxaline |
0 - 150 |
Tenofovir-diphosphate |
NRTI |
PBMC |
Direct injection |
2-chloroadenosine 5’-triphosphate |
0.5 - 100 |
Antiretrovirals – Urine |
Amprenavir |
PI |
Urine |
Protein precipitation |
Quinoxaline |
10 - 10,000 |
Atazanavir |
PI |
Urine |
Protein precipitation |
Quinoxaline |
10 - 10,000 |
Cobicistat |
PK enhancer |
Urine |
Direct injection |
Quinoxaline |
10-4000 |
Darunavir |
PI |
Urine |
Protein precipitation |
Quinoxaline |
4.9 - 5,000 |
Dolutegravir |
INSTI |
Urine |
Direct injection |
Dolutegravir-d5 |
10-4000 |
Efavirenz |
NNRTI |
Urine |
Protein precipitation |
Quinoxaline |
10 - 10,000 |
Elvitegravir |
INSTI |
Urine |
Direct injection |
Elvitegravir-d6 |
10-4000 |
Emtricitabine |
NRTI |
Urine |
Protein precipitation |
2-chloroadenosine |
12.5 - 5,000 |
Etravirine |
NNRTI |
Urine |
Protein precipitation |
Quinoxaline |
4.9 - 5,000 |
Lamivudine |
NRTI |
Urine |
Protein precipitation |
Quinoxaline |
12.5 - 5,000 |
Lopinavir |
PI |
Urine |
Protein precipitation |
Quinoxaline |
14.8 - 15,000 |
Maraviroc |
CCR5 inhibitor |
Urine |
Protein precipitation |
Quinoxaline |
2.5 - 2,500 |
Nevirapine |
NNRTI |
Urine |
Protein precipitation |
Quinoxaline |
10 - 10,000 |
Raltegravir |
INSTI |
Urine |
Protein precipitation |
Quinoxaline |
4.9 - 5,000 |
Rilpivirine |
NNRTI |
Urine |
Protein precipitation |
13C-d4-rilpivirine |
4.9 - 5,000 |
Ritonavir |
PI |
Urine |
Protein precipitation |
Quinoxaline |
4.9 - 5,000 |
Saquinavir |
PI |
Urine |
Protein precipitation |
Quinoxaline |
10 - 10,000 |
Tenofovir |
NRTI |
Urine |
Protein precipitation |
2-chloroadenosine |
12.5 - 5,000 |
Antiretrovirals – Other matrices |
Efavirenz |
NNRTI |
DBMS |
Protein precipitation |
Hexobarbital |
50 - 6000 |
Emtricitabine |
NRTI |
DBMS |
Protein precipitation |
Emtricitabine-13C,15N2 |
16.6 - 5000 |
Dolutegravir |
INSTI |
DBMS |
Liquid-liquid |
Dolutegravir-d5 |
10 - 4000 |
Lamivudine |
NRTI |
DBMS |
Protein precipitation |
Lamivudine-d3 |
16.6 - 5000 |
Tenofovir |
NRTI |
DBMS |
Protein precipitation |
Emtricitabine-13C,15N2 |
4.2 - 1250 |
Efavirenz |
NNRTI |
DBS |
Liquid-liquid |
Hexobarbital |
25 - 5,000 |
Emtricitabine |
NRTI |
DBS |
Protein precipitation |
Emtricitabine-13C,15N2 |
16.6 - 5000 |
Lamivudine |
NRTI |
DBS |
Protein precipitation |
Lamivudine-d3 |
16.6 - 5000 |
Tenofovir |
NRTI |
DBS |
Protein precipitation |
Emtricitabine-13C,15N2 |
16.6 - 5000 |
Rilpivirine |
NNRTI |
CVF |
Protein precipitation |
13C-d4-rilpivrine |
0 - 2000 |
Maraviroc |
CCR5 inhibitor |
CVF |
Protein precipitation |
Maraviroc-d6 |
0.25 - 10 |
Rilpivirine |
NNRTI |
CVL |
Protein precipitation |
13C-d4-rilpivirine |
0 - 20 |
Lamivudine |
NRTI |
Saliva |
Solid phase extraction |
Lamivudine 15N2 13C |
0.5 - 200 |
Maraviroc |
CCR5 inhibitor |
Saliva |
Protein precipitation |
Maraviroc-d6 |
0.25 - 10 |
Raltegravir |
INSTI |
Saliva |
Solid phase extraction |
Raltegravir-d6 |
0.5 - 200 |
Atazanavir |
PI |
Cellulose swabs |
Liquid-liquid |
Atazanavir-d5 |
0 - 75 |
Darunavir |
PI |
Cellulose swabs |
Liquid-liquid |
Darunavir-d9 |
0 - 300 |
Lamivudine |
NRTI |
Cellulose swabs |
Solid phase extraction |
Lamivudine 15N2 13C |
0.153 - 200 |
Lopinavir |
PI |
Celluose swabs |
Liquid-liquid |
Quinoxaline |
0 - 300 |
Maraviroc |
CCR5 inihbitor |
Cellulose swabs |
Liquid-liquid |
Maraviroc-d6 |
0 - 75 |
Raltegravir |
INSTI |
Cellulose swabs |
Solid phase extraction |
Raltegravir-d6 |
0.153 - 200 |
Efavirenz |
NNRTI |
Cervicovaginal swabs |
Protein precipitation |
13C6-Efavirenz |
3.2 - 1088 |
Rilpivirine |
NNRTI |
PVA swabs |
Liquid-liquid |
13C-d4-rilpivirine |
0.025 - 20 |
Lamivudine |
NRTI |
Tissue biopsies |
Protein precipitation |
Lamivudine 15N2 13C |
0.35 - 1000 |
Lamivudine triphosphate |
NRTI metabolite |
Tissue biopsies |
Protein precipitation |
Tenofovir-DP-13C6 |
0.35 - 1000 |
Maraviroc |
CCR5 inhibitor |
Tissue biopsies |
Protein precipitation |
Maraviroc-d6 |
0 - 10 |
Raltegravir |
INSTI |
Tissue biopsies |
Protein precipitation |
Raltegravir-d6 |
0.35 - 1000 |
Rilpivirine |
NNRTI |
Tissue biopsies |
Protein precipitation |
13C-d4-rilpivirine |
0.05 - 40 |
TB Drugs |
Ethambutol |
Antimycobacterial |
Plasma |
Protein precipitation |
Ethambutol-d4-dihydrochloride |
7 - 3,500 |
Isoniazid |
Antimycobacterial |
Plasma |
Protein precipitation |
Isoniazid-d4 |
20 - 10,000 |
Pyrazinamide |
Antimycobacterial |
Plasma |
Protein precipitation |
Pyrazinamide-15N, d3 |
200 - 100,000 |
Rifampicin |
Antimycobacterial |
Plasma |
Protein precipitation |
Rifampicin-d8 |
15 - 7,500 |
HCV drugs |
Daclatasvir |
NS5A inhibitor |
Plasma |
Liquid-liquid |
Daclatasvir-d6 |
10 - 5,000 |
GS-331007 |
Sofosbuvir metabolite |
Plasma |
Liquid-liquid |
13C2-d3- GS-331007 |
10 - 2,500 |
Ledipasvir |
NS5A inhibitor |
Plasma |
Liquid-liquid |
13C2-d6-Ledipasvir |
10 - 2,500 |
Simepravir |
NS3.4A PI |
Plasma |
Liquid-liquid |
Simepravir-d3 |
10 - 5,000 |
Sofosbuvir |
NS5B inhibitor |
Plasma |
Liquid-liquid |
13C-d3-Sofosbuvir |
2.5 - 1250 |
Telapravir + VRT127394 |
NS3.4A PI |
Plasma |
Liquid-liquid |
Telaprevir-d11 |
5 - 5,000 |
Other analytes |
Acetylsalicylic acid |
NSAID |
Plasma |
Protein precipitation |
Acetylsalicylic acid-d3 |
50 - 5000 |
Ethinyl Estradiol |
Estrogen |
Plasma |
Liquid-liquid |
Ethinyl estradiol-d4 |
0.005-0.5 |
Levonorgesterol |
Steroid |
Plasma |
Liquid-liquid |
Levonorgesterol (D-norgesterol)- d7 |
0.05 - 1.5 |
Salicylic Acid |
NSAID |
Plasma |
Protein precipitation |
Salicylic acid-d7 |
50 - 5000 |
Sildenafil |
PDE5 inhibitor |
Plasma |
Protein precipitation |
Sildenafil-d8 |
1.1 - 1,045 |
Desmethyl Sildenfil |
PDE5 inhibitor |
Plasma |
Protein precipitation |
Desmethyl sildenafil-d8 |
0.5 - 514.8 |